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In the Netherlands, the 7-valent pneumococcal con-
jugate vaccine (PCV-7) was implemented in a 3+1-dose 
schedule in the national immunization program for infants 
born after April 1, 2006. To assess the vaccine’s effective-
ness, we compared disease incidence before and after 
vaccine implementation (June 2004–June 2006 and June 
2006–June 2008, respectively). We serotyped 2,552 inva-
sive pneumococcal isolates from throughout the Nether-
lands, covering 25% of the country’s population. Clinical 
characteristics were extracted from hospital records. After 
June 2006, vaccine-serotype invasive pneumococcal dis-
ease (IPD) decreased 90% (95% conﬁ  dence interval [CI] 
68%–97%) in children age eligible for PCV-7; simultaneous-
ly, however, non–vaccine-serotype IPD increased by 71% 
(not signiﬁ  cant), resulting in a 44% total net IPD reduction 
(95% CI 7%–66%). IPD rates did not change for other age 
groups. In the Netherlands, PCV-7 offered high protection 
against vaccine-serotype IPD in vaccinated children, but in-
creases of non–vaccine-serotype IPD reduced net vaccine 
beneﬁ  ts.
S
treptococcus pneumoniae is a leading cause of invasive 
infections, such as meningitis, septicemia, and bacter-
emia, and of more common respiratory tract infections, 
such as pneumonia and otitis media. Young children and 
elderly persons are at particularly high risk for pneumococ-
cal infection (1). In the United States, the introduction in 
2000 of the CRM197-conjugated 7-valent pneumococcal 
vaccine (PCV-7) resulted in a 77% reduction in 2005 of in-
vasive pneumococcal disease (IPD) in children <5 years of 
age from IPD rates reported in 1998–1999 (2). IPD rates in 
children decreased mostly within the ﬁ  rst 2 years after intro-
duction of PCV-7; leveled off in 2002; and then stabilized, 
despite an ongoing decrease of vaccine-serotype IPD, due 
to a gradual increase of non–vaccine-serotype IPD, particu-
larly serotype 19A (2,3). In addition, use of the vaccine in 
children was associated with reduced IPD rates for unvac-
cinated age groups, which resulted from reduced nasopha-
ryngeal colonization of vaccine-serotype S. pneumoniae in 
vaccinated children and concomitant reduced transmission 
(4,5). The cost effectiveness of herd immunity conferred by 
the conjugate vaccine in the United States prompted imple-
mentation of the vaccine in the Netherlands (6). 
Data from the United States concerning both direct 
and indirect vaccine beneﬁ  t, however, cannot be translated 
indiscriminately to European countries because of several 
major differences. Vaccine-serotype coverage by PCV-7 
was lower in European countries (60%–70%) than in the 
United States (>80%) (7), which may leave more room 
for non–vaccine-serotype replacement in European coun-
tries. Second, in the Netherlands (as in most European 
countries), baseline IPD incidence rates are based mainly 
on culture-conﬁ  rmed cases in hospitalized children, result-
ing in markedly lower IPD incidence rates for young chil-
dren in the Netherlands than for those in the United States, 
where blood samples are cultured for more patients. Before 
introduction of PCV-7 in the Netherlands, overall IPD rates 
were 35 cases/100,000 children <2 years of age, of which 
15 cases/100,000 children were meningitis (1). In contrast, 
in the United States, IPD incidence before introduction of 
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PCV-7 peaked at 188 cases/100,000 children <2 years of 
age in 1998–1999 (5), and 10 cases/100,000 children in that 
age group were meningitis (8).
Consequently, introduction of PCV-7 may have affect-
ed IPD incidence in European countries differently than in 
the United States. (9). To assess the effectiveness of PCV-7 
on IPD in the Netherlands, we evaluated the incidence and 
clinical syndromes of IPD in PCV-7–vaccinated and –un-
vaccinated children and in other age groups during the ﬁ  rst 
2 years after implementation of PCV-7.
Materials and Methods
Surveillance and Data Collection
PCV-7 was introduced into the Netherlands’ national 
immunization program (NIP) in June 2006 and was recom-
mended for all infants born after April 1, 2006, at 2, 3, 4, 
and 11 months of age (10). Our study comprised all patients 
with culture-conﬁ  rmed IPD during June 1, 2004–June 1, 
2006 (preimplementation period) and June 1, 2006–June 1, 
2008 (postimplementation period). Isolates were serotyped 
by the Netherlands Reference Laboratory for Bacterial 
Meningitis (NRLBM), which collects nationwide bacterial 
isolates from blood, cerebrospinal ﬂ  uid (CSF), and/or other 
normally sterile bodily ﬂ  uids for laboratory-based surveil-
lance. Isolates from all patients with IPD were submitted 
by 9 sentinel laboratories throughout the country. These 
laboratories covered ≈4.074.412 and ≈4.090.233 residents 
in the preimplementation period and postimplementation 
period, respectively, representing ≈25% of the population 
of the Netherlands. Laboratories were selected on the basis 
of their reliability for submitting pneumococcal isolates; 
they submitted ≈90%–95% of the pneumococcal isolates 
from CSF and ≈83% of pneumococcal isolates from blood 
(1).
Isolates were serotyped as previously described, by 
using antiserum from the Statens Serum Institute (Copen-
hagen, Denmark) (1). Isolates with serotypes 4, 6B, 9V, 
14, 18C, 19F, and 23F, the serotypes contained in PCV-7, 
were considered vaccine serotypes. All other serotypes 
were considered non–vaccine-serotypes.
Clinical Characteristics
Nearly all (97%–98%) IPD cases were in hospitalized 
patients. We retrospectively abstracted information about 
their clinical syndromes and underlying conditions from 
hospital records. Clinical syndromes were categorized as 
meningitis or nonmeningitis IPD (invasive pneumonia, 
IPD with other focus, and bacteremia without focus). Men-
ingitis was deﬁ  ned as CSF culture positive for S. pneumo-
niae (or positive CSF by PCR) and/or clinical diagnosis 
of meningitis in combination with a blood culture positive 
for  S. pneumoniae. Invasive pneumonia was physician-
diagnosed pneumonia and a blood culture positive for S. 
pneumoniae. IPD with other focus was an S. pneumoniae–
positive culture of blood or other normally sterile body ﬂ  uid 
in combination with a clinical focus other than meningitis 
or pneumonia. For bacteremia without focus, no clinical 
focus was identiﬁ  ed. Underlying conditions were classiﬁ  ed 
as immunocompromised conditions or other comorbidities, 
as described previously (1). Case fatality was deﬁ  ned as 
in-hospital death and/or death within 30 days after the ﬁ  rst 
reported blood/CSF culture positive for S. pneumoniae.
Statistical Analyses
To study the effectiveness of the vaccination program, 
we compared age-speciﬁ  c incidences during the preimple-
mentation and postimplementation periods. Incidence rates 
of IPD were calculated as number of cases per 100,000 
persons per year by using 25% of the Dutch population 
on January 1 for each considered year, accounting for the 
25% coverage of surveillance data. Changes in incidence 
rates from the preimplementation to the postimplemen-
tation period were presented as incidence rate ratio with 
95% conﬁ  dence intervals (CI) and as percent changes. We 
compared the preimplementation and postimplementation 
periods with regard to distribution of clinical syndromes, 
comorbidities, and outcomes. Theoretical coverage of IPD 
was based on data from the preimplementation and post-
implementation periods for future 10-valent PCV (PCV-
10, covering PCV-7 serotypes plus serotypes 1, 5, and 7F) 
and 13-valent PCV (PCV-13, covering PCV-10 serotypes 
plus serotypes 3, 6A, and 19A). Proportions were tested 
with χ2 or Fisher exact tests, as appropriate. We consid-
ered p <0.05 to be signiﬁ  cant. Statistical analyses were per-
formed with SAS version 9.1.3 (SAS Institute, Cary, NC, 
USA), Excel 2007 (Microsoft, Redmond, WA, USA), and 
Episheet (11).
Results
During the study period, the NRLBM received 2,649 
S. pneumoniae isolates: 1,297 during the preimplementa-
tion period and 1,352 during the postimplementation pe-
riod. Medical records were assessed for 1,235 (95%) cases 
during the preimplementation period and for 1,317 (97%) 
cases during the postimplementation period. Pneumococ-
cal serotype was available for 1,225 and 1,304 cases (both 
99%), respectively.
IPD Incidence
Overall incidence of IPD remained stable; 15.9 vs. 
15.0 cases/100,000 persons during the postimplementation 
and preimplementation periods, respectively. Incidence 
of vaccine-serotype IPD did not change signiﬁ  cantly. For 
non–vaccine-serotype IPD, incidence increased 13% (95% 
CI 2%–26%; p = 0.02) (Table). In children <2 years of age, 
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including those not vaccinated or incompletely vaccinated, 
the incidence of IPD decreased 35% (95% CI 4%–56%; 
p = 0.006), from 34.5 cases/100,000 persons in the pre-
implementation period to 22.5 cases/100,000 persons in 
the postimplementation period (Table). Incidence of vac-
cine-serotype IPD declined by 67% (95% CI 41%–81%; 
p<0.0001), from 24.3 to 8.0 cases/100,000 persons. In con-
trast, non–vaccine-serotype IPD incidence increased, but 
not signiﬁ  cantly, from 10.1 to 14.5 cases/100,000 persons 
(p = 0.40).
Among children born after April 1 2006 (i.e., age-eli-
gible for vaccination according to the NIP), the incidence 
rate of vaccine-serotype IPD in the postvaccination period 
(2.4 cases/100,000 persons) decreased 90% (p<0.0001) 
compared with that for an age-matched group in the pre-
implementation period (24.2 cases/100,000) (Figure 1). 
Although not signiﬁ  cant because of low numbers, the in-
cidence of non–vaccine-serotype IPD had risen by 71%, 
from 9.8 to 16.8 cases/100,000 persons (p = 0.12), leading 
to a total net reduction of 44% (95% CI 7%–66%; p = 0.02) 
in the birth group age-eligible for vaccination.
Three vaccine-serotype IPD cases occurred among 
children born after April 1, 2006; 2 cases after 1 vaccine 
dose (serotypes 9V and 23F) and 1 case within 1 week af-
ter the second dose (serotype 9V, isolated from CSF). In 
infants <2 years of age born before April 1, 2006 (i.e., age-
ineligible for PCV-7), no changes occurred in vaccine- or 
non–vaccine-serotype IPD rates in the postimplementation 
period compared with those for age-matched children in 
the preimplementation period.
Serotype Distribution
After introduction of PCV-7, for all vaccine serotypes, 
the number of IPD cases among the total population re-
mained stable, except for serotype 19F (44 vs. 23 cases; 
p = 0.004). Also, proportions of non–vaccine-serotype 1 
and 22F signiﬁ  cantly increased (Figure 2). Among children 
born after April 1, 2006, serotypes 1 and 7F increased in 
comparison with those for age-matched infants in the pre-
implementation period (Figure 3). For serotype 6A, 6C and 
19A, no signiﬁ  cant changes occurred in any age group.
Clinical Characteristics
Among children <2 years of age, incidence rates 
decreased for all clinical syndromes to approximately 
the same extent (Figure 4). Rates of meningitis declined 
34% from 14.7 to 9.6 cases/100,000 children (29 vs. 18 
cases) and of nonmeningitis IPD 35% from 19.8 to 12.9 
cases/100,000 children in this age group (39 vs. 24 cases). 
Of these children, 30% (20/66) had comorbidities in the 
preimplementation period, compared with 9% (4/44) in 
the postimplementation period (p<0.001). In all other age 
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Table. Incidence rates of invasive pneumococcal diseases before and after implementation of 7-valent pneumococcal conjugate 
vaccine, the Netherlands* 
Serotypes by patient age 
group, y 
Preimplementation period 
(June 2004–June 2006)
Postimplementation period 
(June 2006–June 2008)
Preimplementation vs. 
postimplementation
No. cases Rate No. cases Rate IRR (95% CI) p value†
Total 
 All  ages  1,225 15.0 1,304 15.9 1.06  (0.98–1.15)  0.14
 <2  68 34.5 42 22.5 0.65 (0.44–0.96) 0.006
 2–4  25 8.1 26 8.7 1.07 (0.62–1.86) 
 5–49  206 4.1 231 4.7 1.13 (0.94–1.37) 
 50–64  254 16.7 292 18.5 1.11 (0.94–1.31) 
 >65 672 58.8 713 60.2 1.02 (0.92–1.14) 
Vaccine serotypes‡ 
 All  ages  570 7.0 561 6.9 0.98 (0.87–1.10) 
 <2  48 24.3 15 8.0 0.33 (0.19–0.59) <0.0001
 2–4  17 5.5 17 5.7 1.03 (0.53–2.02) 
 5–49  69 1.4 70 1.4 1.02 (0.73–1.43) 
 50–64  114 7.5 129 8.24 1.09 (0.85–1.40) 
 >65 322 28.2 330 27.9 0.99 (0.85–1.15) 
Nonvaccine serotypes§ 
 All  ages  656 8.0 743 9.1 1.13 (1.02–1.26) 0.02
 <2  20 10.1 27 14.5 1.43 (0.80–2.55) 
 2–4  8 2.6 9 3.0 1.16 (0.45–3.01) 
 5–49  137 2.8 161 3.3 1.19 (0.94–1.49) 
 50–64  140 9.2 163 10.3 1.12 (0.89–1.41) 
 >65 350 30.6 383 32.4 1.06 (0.91–1.22) 
*Rate is cases/100,000 persons. IRR, incidence rate ratio; CI, confidence interval. Boldface indicates significant differences (p<0.05). 
†p values shown <0.15; incidence rates pre vs. postimplementation period. Calculated by using Fisher exact test; all p values are 2 sided. 
‡Streptococcus pneumoniae serotypes 4, 6B, 9V, 14, 18C, 19F, and 23F. 
§All other S. pneumoniae serotypes. Pneumococccal Conjugate Vaccine, the Netherlands
groups, clinical syndromes did not change from the pre-
implementation to the postimplementation period, except 
for a 124% rise in rates of non–vaccine-serotype meningitis 
for persons 5–49 years of age (95% CI 19%–320%; p = 
0.01). The proportions of adult patients with comorbidities   
and immunocompromising conditions were similar in the 
preimplementation and postimplementation periods: 71% 
vs. 74% and 19 vs. 22%, respectively. For the vaccinated 
group of children, the case-fatality rate remained stable 
(9.3% vs. 8.3%) in the preimplementation and postimple-
mentation periods, respectively. In other age groups, case-
fatality rates did not differ (data not shown).
Estimated Coverage by Future Vaccines
Among vaccination-eligible children, the additional 
coverage rates in the preimplementation and postimple-
mentation periods were 2.2% (1/45 cases) and 54.2% (13/ 
24 cases) for PCV-10 (p<0.0001). For PCV-13, they were 
19.6% (8/45 cases) and 66.7% (16/24 cases) (p<0.001) 
(Figure 5).
Discussion
The total net IPD reduction of 35% among children 
<2 years of age observed in the Netherlands differs from 
the favorable results reported in the United States, where 
a 69% decrease in IPD within the ﬁ  rst 2 years after PCV-7 
introduction was reported despite lower vaccine uptake 
(i.e., estimates of national immunization coverage) rates in 
the United States than in the Netherlands (2,12). US esti-
mates for PCV-7 uptake among children born in 2001 who 
received >1 and >3 doses were 89% and 68%, respectively 
(2). In contrast, in the Netherlands, 94.4% of all infants born 
in 2006 were fully vaccinated at 2 years of age (12). Also, 
the decrease in meningitis incidence in the Netherlands 
was lower than that for US infants <2 years of age (34% 
vs. 59%), whereas during the preimplementation period, 
meningitis incidence was comparable in the 2 countries. In 
the ﬁ  rst 2 years after implementation in the United States, 
IPD requiring hospitalization decreased 63% in children <2 
years (5). In contrast, all IPD in this age group decreased 
35%, and almost all reported IPD cases occurred in hospi-
talized patients.
The difference between the impact of PCV-7 in the 
Netherlands and the United States may be attributable to 
the lower proportion of vaccine-serotype cases covered 
by PCV-7 before implementation in the Netherlands and 
in Europe. Reports about PCV-7 effectiveness by other 
European countries support this observation. In Germany 
and Norway, PCV-7 effectively prevented disease in the 
youngest age groups during the ﬁ  rst years after implemen-
tation, without major increase of non–vaccine-serotype 
IPD (13,14). In Spain, vaccine-serotype IPD decreased 
after PCV-7 implementation; however, non–vaccine-sero-
type IPD increased (15,16). In France, 3 years after PCV-7 
introduction, overall IPD cases decreased 21% among 
children of <2 years of age, when 44%–56% of children 
were vaccinated (17). In addition, similar to ﬁ  ndings in the 
Netherlands, a simultaneous increase in IPD from non–
vaccine-serotype pneumococci reduced the net beneﬁ  t 
of vaccination. Differences in surveillance systems, tem-
poral  ﬂ  uctuations of circulating serotypes, antimicrobial 
drug resistance and penicillin susceptibility of circulating 
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Figure 1. Incidence of invasive pneumococcal disease in children 
<2 years of age in the birth group born after April 1, 2006 (age 
eligible for 7-valent pneumococcal conjugate vaccine [PCV-7]) and 
children born before April 1, 2006 (age noneligible for PCV-7), in the 
postimplementation period compared with age-matched children 
in the preimplementation period, the Netherlands. Incidence per 
100,000 children <2 years of age per year; Pre, preimplementation 
period (June 2004–June 2006); post, postimplementation period 
(June 2006–June 2008).
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Figure 2. Serotype distribution of 
invasive pneumococcal disease 
with regard to preimplementation 
and postimplementation of 7-valent 
pneumococcal conjugate vaccine 
(PCV-7); among persons of all ages, 
the Netherlands. Preimplementation 
period June 2004–June 2006; 
postimplementation period June 
2006–June 2008; *p<0.05; proportion 
of serotypes preimplementation vs. 
postimplementation period. Calculated 
using Fisher exact test; all p values are 
2 sided.
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pneumococcal strains, vaccination schedules, vaccine up-
take, and blood sampling practices also may play a role in 
the differences between countries (9,18). Like Norway, a 
reduced-dose PCV-7 schedule has been introduced in the 
United Kingdom. In the ﬁ  rst years after implementation, 
surveillance data from the United Kingdom have tended to 
show a major decline in vaccine-serotype IPD in infants <2 
years of age concomitant with a substantial rise in non–vac-
cine-serotype IPD, reducing net vaccine beneﬁ  ts (19,20). 
Unlike in the United States, where IPD in children <2 years 
of age stabilized within 2 years after introduction of the 
vaccine (2), in Europe and in our study, incidence has not 
yet stabilized. Our results emphasize the need for continued 
surveillance to monitor the long-term public health beneﬁ  ts 
of the vaccination program.
Despite the high vaccination uptake in the Netherlands, 
we observed no indication of herd immunity in other age 
groups during the ﬁ  rst 2 years after implementation, ex-
cept for a decrease in serotype 19F. This observation may 
be explained by the relatively short evaluation period of 2 
years, a relatively small vaccinated group (2.25%) of the 
total population, and lack of a catch-up program for older 
children. In Australia and the United Kingdom, which have 
catch-up programs for children <2 years of age, decreases 
in vaccine-serotype IPD in unvaccinated children within 
3 years after PCV-7 implementation have been reported 
(21,22).
The small increase we found in non–vaccine-serotypes 
1 and 7F among vaccinated children could be attributed to 
temporal ﬂ  uctuations (18,23). The numbers in our study 
were too small and the period we studied too short to enable 
us to draw ﬁ  rm conclusions about changes in serotype-spe-
ciﬁ  c incidence. Serotype 1 also has increased in other age 
groups and may cause local outbreaks, as observed in other 
countries before the implementation of PCV-7 (24,25). In 
our study, we could not ﬁ  nd evidence of outbreaks associ-
ated with serotype 1.
The increase in non–vaccine-serotype IPD in the vac-
cinated age group was not explained by more children with 
comorbidities or immunocompromised conditions in the 
years after introduction and not associated with a change 
in the case-fatality rate. Longer follow-up is needed to as-
sess whether this increase and that in non–vaccine-serotype 
IPD in the overall population are temporary or are vaccine 
related. Several countries have suggested that use of PCV-7 
might enhance the emergence of serotype 19A pneumococ-
cal clones, often associated with penicillin resistance (26). 
In the Netherlands, where use of antimicrobial drugs is re-
stricted, few penicillin-resistant pneumococcal isolates were 
received during the study period; 98.8% were susceptible 
to penicillin (MIC <0.06 mg/L), 0.8% were intermediately 
susceptible (0.06–1.0 mg/L), and 0.4% were resistant (>1.0 
mg/L). We did not see a prominent increase in serotype 
19A among patients; only 1 isolate was penicillin resistant 
(>1.0 mg/L) in the ﬁ  rst 2 years after PCV-7 implementa-
tion. However, increase in serotype 19A pneumococci was 
found in a randomized controlled study of nasopharyngeal 
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Figure 3. Serotype distribution of invasive pneumococcal disease 
cases among children born after April 1, 2006 (age eligible for 
7-valent pneumococcal conjugate vaccine [PCV-7]) in the 
postimplementation period compared with age-matched children in 
the preimplementation period, the Netherlands. Preimplementation 
period, June 2004–June 2006; postimplementation period, June 
2006–June 2008; other serotypes are 15A, 16F, 22F, 3, 33F, 5, and 
9N. *p<0.05; preimplementation vs. postimplementation periods. 
Proportions calculated using Fisher exact test; all p values are 
2 sided.
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Figure 4. Age group–speciﬁ  c  distribution 
of clinical invasive pneumococcal disease 
(IPD) syndromes in the preimplementation 
and postimplementation periods of 7-valent 
pneumococcal conjugate vaccine (PCV-7), 
the Netherlands. Incidence is IPD cases 
per 100,000 persons per year. Pre, 
preimplementation period (June 2004–June 
2006); post, postimplementation period 
(June 2006–June 2008).Pneumococccal Conjugate Vaccine, the Netherlands
carriage among vaccinated children compared with unvac-
cinated controls before national implementation of PVC-7 
(27). Also, no changes in distribution of serotype 6A or 6C 
were reported. Theoretical coverage of the future conjugate 
vaccines PCV-10 and PCV-13 increased in the postimple-
mentation period in vaccination-eligible children. In all 
other age groups, no changes were observed. Future vac-
cines need to be considered to improve the net beneﬁ  t of 
immunization against pneumococcal diseases.
Some limitations should be acknowledged. Although 
our study covered ≈25% of the population of the Nether-
lands, numbers of IPD cases and serotype distribution are 
small and need cautious interpretation. After 2 years, ﬁ  nal 
vaccine beneﬁ  ts cannot be established. Furthermore, dis-
tribution of serotypes among invasive pneumococci may 
ﬂ  uctuate over time, and temporal trends in serotype may 
vary across geographic regions and independent of PCV-7 
implementation (18,23). Although the 9 sentinel laborato-
ries submitted 25% of all pneumococcal isolates received 
by the NRLBM (nationwide coverage 95%), the popula-
tion under surveillance might be overestimated because 
the laboratories were selected on reliability of stable pneu-
mococcal isolates submission over the years. Second, our 
surveillance system depended on how well the 9 sentinel 
laboratories were submitting their isolates, and small shifts 
in the proportion of submission to the NRLBM cannot be 
excluded (14). Blood culture rates may have inﬂ  uenced 
IPD incidence reported in this study (28). However, these 
changes are not likely to be substantial. National IPD in-
cidence rates estimated from the number of isolates sub-
mitted by the 9 sentinel laboratories are similar to those of 
neighboring countries, e.g., Denmark and the United King-
dom, that have comparable health system practices (29). 
The rates of submission of blood and CSF isolates for chil-
dren <5 years of age have been stable in the Netherlands 
for the past 10 years at ≈90%. Enhanced surveillance with 
such high submission rates and stable overall IPD rates 
cannot explain the 71% increase of nonvaccine serotypes. 
Also, and most important, the changes in IPD serotype dis-
tribution occurred only in vaccination-eligible infants. No 
changes in serotype distribution or signs of herd immunity 
were observed in unvaccinated infants. A potential bias by 
enhanced awareness would cause differences also in this 
group. Long-term surveillance data will elucidate whether 
the changes in serotype distribution in vaccinated and un-
vaccinated persons remain. Lastly, in the Netherlands, no 
changes in diagnostic methods or blood culture practices 
have been implemented recently.
Strengths of our study include the detailed information 
about the IPD cases and the established high degree of vac-
cine uptake for the NIP in the Netherlands (≈95% of infants 
of <1 year of age are fully vaccinated) (12). Vaccination 
with the 23-valent pneumococcal polysaccharide vaccine 
has not been routinely recommended for elderly persons, 
and uptake has been negligible in the Netherlands; thus, 
any inﬂ  uence of this vaccine can be excluded (30). The low 
proportion of penicillin-resistant pneumococcal isolates 
and the densely living but relatively homogeneous popula-
tion make the Netherlands particularly suitable for describ-
ing vaccine effects. Our study provides accurate data from 
a representative group of the Dutch population with fairly 
detailed information about the distribution of clinical syn-
dromes and presence of comorbidities.
Shortly after introduction of PCV-7 vaccination for 
infants, the direct vaccine effectiveness on IPD caused by 
vaccine-serotype pneumococci appeared high in the Neth-
erlands. However, the net beneﬁ  t is partly offset by the in-
creased incidence of nonvaccine serotypes. For this reason, 
future conjugate vaccines may be valuable in further re-
ducing IPD incidence. These results further emphasize the 
need for ongoing surveillance.
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